Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
World game at war: why some European nations have threatened a World Cup boycott 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
EMERYVILLE, Calif., May 04, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, May 9th @ 4:30pm Eastern Time/1:30pm Pacific Time
| Toll Free: | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 7186111 |
| Webcast: | http://public.viavid.com/index.php?id=129538 |
| Replays, available through May 23rd | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Replay PIN: | 7186111 |
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
